| Description |
1 online resource (278 p.) |
| Series |
Frontiers in Cardiovascular Drug Discovery Ser |
|
Frontiers in Cardiovascular Drug Discovery Ser
|
| Contents |
Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- The Lipid Hypothesis: From Resins to Proprotein Convertase Subtilisin/Kexin Type-9 Inhibitors -- Sudarshan Ramachandran1,2,3, Mithun Bhartia4,5 and Carola S. König3 -- INTRODUCTION -- CHOLESTEROL -- Early Evolution of the Relationship between Cholesterol and Atherogenesis -- LONGITUDINAL PROSPECTIVE OBSERVATIONAL STUDIES AND CVD RISK ALGORITHMS -- INTERVENTIONAL STUDIES WITH CLINICAL EVENTS AS OUTCOMES -- Randomised Controlled Bile Sequestrants Trials |
|
Randomised Controlled Statin Trials -- Randomised Controlled Ezetimibe Trials -- Randomised Controlled PCSK9 Inhibitor Trials -- THE RECENT CASE AGAINST THE LIPID HYPOTHESIS -- ROLE OF OTHER LIPID LOWERING AGENTS -- ROLE OF ANTI-INFLAMMATORY THERAPY -- REFINING THE LIPID HYPOTHESIS: IDENTIFICATION OF SUBGROUPS DEMONSTRATING EVEN GREATER BENEFIT -- CONCLUSION -- DISCLOSURE STATEMENT -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- The Role of SGLT2i in the Prevention and Treatment of Heart Failure |
|
Hasan AlTurki1, Ahmed AlTurki2, Mark Sherman3, Abhinav Sharma2 and Thao Huynh2,* -- INTRODUCTION -- HEART FAILURE -- MECHANISMS OF ACTION OF SGLT2 AND SGTL2I -- Glucose Homeostasis -- Cardiovascular Effects of SGLT2i -- Nephroprotective Effects of SGLT2I -- CV OUTCOMES IN PATIENTS WITH T2DM -- RENAL OUTCOMES IN PATIENTS WITH T2DM AND CHRONIC KIDNEY DISEASE (CKD) -- HEART FAILURE -- PERIPHERAL ARTERIAL DISEASE -- ACUTE HEART FAILURE -- REAL-WORLD DATA -- CURRENT SGLT2I USES -- CURRENT USE OF SGLT2 INHIBITORS IN CLINICAL PRACTICE -- PRACTICAL CONSIDERATIONS WITH SGLT2I PRESCRIPTION |
|
FUTURE DIRECTIONS AND ONGOING TRIALS -- CONCLUSIONS -- CONSENT FOR PUBLICATION -- CONFLICTS OF INTEREST -- ACKNOWLEDEGEMENTS -- REFERENCES -- Natural Products and Semi-Synthetic Compounds as Antithrombotics: A Review of the Last Ten Years (2009-2019) -- Angelo Piato1,* and Cedric Stephan Graebin2,* -- INTRODUCTION -- NATURAL PRODUCTS WITH ANTITHROMBOTIC ACTIVITY -- Antithrombotic Molecules Obtained from Marine-based Sources -- Antithrombotics from microorganisms -- Antithrombotics from Plant-based Sources -- Semi-synthetic compounds with antithrombotic activity -- CONCLUSION -- ABBREVIATIONS |
|
CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Transient Receptor Potential Channels: Therapeutic Targets for Cardiometabolic Diseases? -- Leidyanne Ferreira Gonçalves, Thereza Cristina Lonzetti Bargut and Caroline Fernandes-Santos* -- INTRODUCTION -- TRP CHANNELS -- TRPA (ankyrin) Family -- TRPC (canonical) Family -- TRPM (melastatin) Family -- TRPML (mucolipin) Family -- TRPP (polycystin) Family -- TRPV (vanilloid) Family -- TRP CHANNELS AND CARDIOVASCULAR DISEASES -- TRP Expression -- TRPA1 -- TRPC -- TRPM -- TRPV |
| Summary |
Frontiers in Cardiovascular Drug Discovery is a book series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The book series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology. The fifth volume of the series covers |
| Notes |
Description based upon print version of record |
| Subject |
Cardiovascular agents.
|
|
Cardiovascular Agents
|
|
Cardiovascular agents
|
| Form |
Electronic book
|
| Author |
Atta-ur-Rahman
|
|
Choudhary, M. Iqbal
|
| ISBN |
981141324X |
|
9789811413247 |
|
